Monday, September 6, 2010
"Concise industry news from the US pharmaceutical industry..."
Blog
Where our team of guest writers discuss what they think about the current NGP US Issues.
Peter Duncan
Director of Business Development
Director of Business Development
Can digital pathology save drug development?
Peter Duncan of Definiens discusses the potential of digital pathology.07 Jul 2010
Pharmaceutical M&A: New dynamics
Hogan & Hartson | www.hhlaw.com
No Comments
The pharmaceutical industry has experienced a huge wave of mergers and acquisitions activity in the past several years. Having enjoyed enormous success and profitability over the past 20 years, however, pharmaceutical companies now face several significant threats. What role will M&A activities play as companies try to address these factors?
More like this...
-
Strategic outsourcing: the viable option
This article looks at two very different approaches to outsourcing.Read more -
Shaping third party production
Just as in the automobile, electronics and aerospace industries, third party or sub-contracted manufacturing has become an essential strategy for pharmaceutical laboratories.Read more -
A new approach to outsourced pharmaceutical man...
Pharmaceutical companies face a myriad of challenges day in and day out.Read more -
The benefits of checkweighing
Looking at checkweighers that reassure operators of compliant production, product completeness and repeatable quality control.Read more -
Risk and quality management ? a supplier?s pers...
In September 2004, the FDA issued a final report on its Pharmaceutical Manufacturing Initiative (PMI).Read more -
Don?t drop the ball
Manufacturers are juggling a plethora of issues in order to stay at the topRead more
Disclaimer: All comments posted in a personal capacity
No Comments Have Been Submitted
Disclaimer: All comments posted in a personal capacity
Source: www.ngpharma.com© 2010 GDS Publishing Ltd. All rights reserved.